Surgical management of BRCA-mutation carriers: A single institution experience

• Published in: European journal of surgical oncology Vol. 48; no. 8; pp. 1706 - 1712
• Main Authors: Gentile, Damiano, Losurdo, Agnese, Sagona, Andrea, Zuradelli, Monica, Gatzemeier, Wolfgang, Barbieri, Erika, Testori, Alberto, Errico, Valentina, Bianchi, Paolo, Biondi, Ersilia, Torrisi, Rosalba, Santoro, Armando, Tinterri, Corrado
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.08.2022
• Subjects: BRCA; Breast cancer; Breast-conserving therapy; Mastectomy; Salpingo-oophorectomy; Mastectomy; BRCA; Salpingo-oophorectomy; Breast cancer; Breast-conserving therapy
• ISSN: 0748-7983; 1532-2157; 1532-2157
• DOI: 10.1016/j.ejso.2022.04.024

The optimal surgical management of BRCA-mutation carriers remains a subject of debate. To evaluate the appropriateness of breast cancer (BC) treatment, the oncological outcomes of BRCA-mutation carriers treated either with breast-conserving therapy (BCT) or mastectomy were compared. Additionally, the role of bilateral salpingo-oophorectomy (BSO) and potential independent predictive factors for BC treatment were analyzed. We retrospectively reviewed all the consecutive patients with a pathogenic germline mutation in the BRCA1/2 genes tested at our Institution between July 2008 and October 2018. Primary end-points were disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS). The characteristics and outcomes of 124 BRCA-associated BC patients were analyzed. Overall, 69 (55.7%) and 55 (44.3%) patients underwent BCT and mastectomy, respectively; 72 (58.1%) patients underwent BSO. After a median interval of 13.3 months, 24 patients underwent mastectomy after primary BCT. There was no significant difference in terms of DFS, DDFS, and OS between patients treated with BCT or mastectomy (p = 0.39,p = 0.27,p = 0.265, respectively). Patients treated with BSO had significantly better DDFS and OS compared to ovarian conservation (p = 0.033,p = 0.040, respectively). Three independent predictive factors for BCT were identified: age ≤41 years, genetic testing performed post-operatively, and breast tumors ≤21 mm. Our data suggest that BRCA-mutation carriers treated with BCT present similar oncological outcomes compared to mastectomy. Ovarian preservation decreases survival. Young BRCA-mutated patients with small BCs may not need up-front mastectomy, and BSO might be performed when ovarian cancer risk epidemiologically rises and potential reproductive desire is fulfilled.